Friday, November 7, 2008

Look for Crestor's "Jupiter" to Rock Schering -- on Sunday (and Monday, on the NYSE). . . .


I'll have There now is much more here come Sunday, the 9th, but know now that Crestor is -- acoording to many Wall Street analysts -- widely expected to double its market share (~$3 billion per year in 2008, to ~$6 billion per year by 2012), as a result of the huge success of AstraZeneca's "Jupiter" study.

And it is very likely to take almost all of that share from Schering -- and Vytorin/Zetia.

More here, on Sunday -- from Louisiana.

2 comments:

Anonymous said...

apparently there will be a scientific session at the meeting talking specifically about Vytorin.

Condor said...

And it looks like the AHA web-mavens will provide LIVE streaming video-feeds of the scientific sessions!

I'll be watching tomorrow, and on Sunday, for a Vytorin-specific session!

If the techs have it working at AHA, and such a session transpires, I'll open an anchored window on my site, to be able to view the video, right here.

Thanks -- great lead!